NCT05766007Completed
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum: An Observational Cohort Study
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about how long-acting injectable antipsychotic (LAIA) medications are affected by the changes that take place in the body during pregnancy, and how much an unborn baby is exposed to. The investigators are also interested in the amount of these drugs that enters into breastmilk and taken by babies during breastfeeding. In addition to their regular clinic visits to receive long-acting mental health medicine injection, participants will be invited for up to four study visits between day 2 and 14 after the injection. This will happen only once during pregnancy, and once during the breastfeeding period to collect a few drops of blood on special filter paper card from the finger using safety lancet. A few drops of breastmilk will also be collected. Immediately after delivery, a few drops of blood will be collected from the mother, umbilical cord and the baby heel. The investigators will use these samples to determine the amount of the drug in the body during pregnancy and compare this to the amount during the breastfeeding period. Additionally, every month during the third trimester, and during the first 3 months postpartum, participants will complete a questionnaire (using the Liverpool University Neuroleptic Side Effect Scale) to document how they are feeling. Clinical improvement will be documented by the primary care provider using the Clinical Global Impressions Scale. Findings from this study are expected to help healthcare providers to understand these drugs better so that they can make informed decisions about if and how to use these drugs in women who become pregnant or are breastfeeding.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 168 (actual)
- First submitted
- 30 Jan 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 21 Nov 2025
- Lead sponsor
- University of Liverpool
- Diseases
- Schizophrenia
- NCT number
- NCT05766007
What you commit to
- Study type: Observational
- Participants enrolled: 168
- From 1 Aug 2023 to the primary completion date, 21 Nov 2025
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Record of poor medication adherence.
- Concurrent use of agents with known or uncertain interaction with study drug.
Other illness
- Known hypersensitivity to study medication.
Other
- Unable to understand study information.
- Unable to provide written informed consent.
- Personal circumstances will not allow completion of the schedule of study activities.
- Currently experiencing severe pregnancy related complications
Who the study is looking for
- Currently pregnant or breastfeeding.
- If pregnant, plans to deliver within the facility.
- Diagnosis of schizophrenia, mania or other psychoses.
- Prescription of long-acting injectable antipsychotic (Risperidone, Paliperidone palmitate, Fluphenazine decanoate, Flupenthixol decanoate and Zuclopenthixol decanoate) as maintenance therapy started before study entry.
- Scheduled to receive at least one injection before delivery (if pregnant) or before week 12 postpartum (if breastfeeding).
- At least 18 of age at study entry.
Age in the registry: 18 years to 49 years · Sex: Female · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neuropsychiatric Hospital Coordinator of this site? Confirm its status | Abeokuta | Nigeria | Unknown status |
| Neuropsychiatric Specialist Hospital Coordinator of this site? Confirm its status | Akure | Nigeria | Unknown status |
| Obafemi Awolowo University Teaching Hospital Coordinator of this site? Confirm its status | Ile-Ife | Nigeria | Unknown status |
| Federal Neuropsychiatric Hospital Coordinator of this site? Confirm its status | Kaduna | Nigeria | Unknown status |
| Federal Medical Centre Coordinator of this site? Confirm its status | Makurdi | Nigeria | Unknown status |
| Federal Neuropsychiatric Hospital Coordinator of this site? Confirm its status | Yaba | Nigeria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.